OSI Pharmaceuticals Inc. Q2 2008 Earnings Call Transcript Gabe Leung - EVP and President of Oncology Anker Lundemose - President of our Diabetes/Obesity Business Analysts Joel Sendek - Lazard Capital Markets Maged Shenouda - UBS May-Kin Ho - Goldman Sachs Matt Roden - JPMorgan Mike King - Rodman ...
CombinatoRx Highlights Progress in Key Programs at 2008 R&D Day - CombinatoRx, Incorporated (NASDAQ: CRXX) today provided a detailed review of selected therapeutic programs and a general company update at its annual Research and Development (R&D) day at its corporate headquarters in Cambridge, MA...
Duska Therapeutics Submits Phase 3 ATPace Protocol to FDA for Comment /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc.('Duska') announced today that it has submitted for comment a synopsis of a proposed Phase 3 clinical study for its lead drug, ATPace(TM), to the U.S.
Food and Drug...
Biodel Announces Publications Demonstrating Superior Metabolic Profile of VIAject Compared to the Rapid-acting - Biodel Inc.(Nasdaq: BIOD) announced today the publication of positive findings from studies demonstrating the superior metabolic profile of VIAject(TM) ultra rapid-acting insulin compared to the rapid-acting analog, Humalog(R), and...
ISENTRESS(R) (raltegravir), Merck's First in Class Integrase Inhibitor, Suppressed HIV-1 Viral Load and Increa ISENTRESS(R) (raltegravir), Merck's first-in-class HIV-1 integrase inhibitor, suppressed HIV-1 viral load and increased CD4 cell counts through 48 weeks of combination therapy with other anti-HIV medicines compared to placebo in combination...
Sangamo BioSciences Reports Second Quarter 2008 Financial Results RICHMOND, Calif., July 23 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc.today reported second quarter 2008 financial results and accomplishments.
For the second quarter ended June 30, 2008, Sangamo reported a consolidated net loss...
Sangamo BioSciences Reports Second Quarter 2008 Financial Results RICHMOND, Calif., July 23 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc.today reported second quarter 2008 financial results and accomplishments.
For the second quarter ended June 30, 2008, Sangamo reported a consolidated net loss...
Elan Reports Second Quarter 2008 Financial Results DUBLIN, Ireland--(BUSINESS WIRE)--Elan Corporation, plc today announced its second quarter 2008 financial results and provided a business update.Commenting on Elans business, Kelly Martin, Elans president and chief executive officer, said...
Nuvelo Reports Second Quarter 2008 Financial Results SAN CARLOS, Calif., July 23 /PRNewswire-FirstCall/ -- Nuvelo, Inc.today announced second quarter 2008 financial results and accomplishments.
For the second quarter ended June 30, 2008, Nuvelo reported a net loss of $0.2 million or $0.00...
Nuvelo Reports Second Quarter 2008 Financial Results SAN CARLOS, Calif., July 23 /PRNewswire-FirstCall/ -- Nuvelo, Inc.today announced second quarter 2008 financial results and accomplishments.
For the second quarter ended June 30, 2008, Nuvelo reported a net loss of $0.2 million or $0.00...
Nuvelo Reports Second Quarter 2008 Financial Results SAN CARLOS, Calif., July 23 /PRNewswire-FirstCall/ -- Nuvelo, Inc.today announced second quarter 2008 financial results and accomplishments.
For the second quarter ended June 30, 2008, Nuvelo reported a net loss of $0.2 million or $0.00...
Is it end of inhalable exubera In October 2007, Pfizer, one of the largest global pharmaceutical companies, took the market by surprise by announcing its decision to discontinue the production of Exubera [rDNA origin], the inhalable powder formulation of insulin for the...
The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overal - Nexavar is First Approved Systemic Therapy to Treat the Disease - WAYNE, N.J.and EMERYVILLE, Calif., July 23 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc.
today announced that The New...
Genzyme Corp. Q2 2008 Earnings Call Transcript Thanks, Mary Ann, and welcome everyone to Genzyme Corporation's second quarter Earnings Call.On this call, we will be making forward-looking statements, including providing EPS guidance, discussing our product development plans and...
FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Trace BOSTON, July 23 /PRNewswire/ -- FluoroPharma Inc., a company developing breakthrough molecular imaging agents for the Positron Emission Tomography (PET) market, announced positive Phase I results for BFPET, its novel Fluorine-18...
Avigen's AV650 Patent Strategy Leads to Expanded Development Agreement (PRIME NEWSWIRE) -- Avigen, Inc.(Nasdaq:AVGN), a biopharmaceutical company innovating therapeutics for neurological care, today announced an amendment to the company's contract with Sanochemia Pharmazeutika AG, Avigen's development...
Seattle Genetics Inc. Q2 2008 Earnings Call Transcript Good afternoon ladies and gentlemen.Thank you for standing by.
Welcome to the Seattle Genetics second quarter 2008 financial results conference call.
(Operator instructions) This conference is being recorded today, Tuesday July 22,...
Dyax Corp. Q2 2008 Earnings Call Transcript Dyax Corp.(DYAX) Executives Henry Blair Chairman, President and CEO Gustav Christensen EVP and Chief Business Officer Bill Pullman EVP and Chief Development Officer Analysts Mark Monane Needham & Company Jason Kolbert SIG Phil...
CombinatoRx Highlights Progress in Key Programs at 2008 R&D Day CombinatoRx, Incorporated (NASDAQ: CRXX) today provided a detailed review of selected therapeutic programs and a general company update at its annual Research and Development (R&D) day at its corporate headquarters in Cambridge, MA....
CombinatoRx Highlights Progress in Key Programs at 2008 R&D Day CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX - News) today provided a detailed review of selected therapeutic programs and a general company update at its annual Research and Development (R&D) day at its...
Forest Laboratories Inc. F4Q09 (Qtr End 6/30/08) Earnings Call Transcript Frank Perier, Jr - SVP, Finance and CFO Larry Olanoff - President and COO Analysts Rich Silver - Lehman Brothers Greg Gilbert - Merrill Lynch Frank Pinkerton - Banc of America Securities Corey Davis - Natixis Bleichroeder Annabel Samimy --...
Biogen IDEC, Inc. Q2 2008 Earnings Call Transcript James C.Mullen - President and CEO Bill Sibold - Sr.
VP, US Commercial Al Sandrock - Sr.
VP, Neurology Research and Development Paul J.
Clancy - EVP and CFO Analysts Michael Aberman - Credit Suisse Geoffrey Meacham - JPMorgan Yaron...
From Whole-Gland to Targeted Cryoablation for the Treatment of Unilateral or Focal Prostate Can Division of Urologic Surgery and Duke Prostate Center (DPC) Department of Surgery Duke University Medical Center Durham, North Carolina The intermediate and long-term results of primary full-gland cryoablation for localized prostate cancer...
Methylgene and Celgene announce precautionary suspension of new enrollments into MGCD0103 clinical trials Montreal, Quebec and Summit, NJ - MethylGene Inc.(TSX:MYG) and Celgene Corporation today announced that, at the recommendation of a standing internal safety committee, the companies are temporarily suspending enrollment of new patients...
CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima Using I - State-of-the-Art PET Study Confirms Tyrima Exhibits Excellent Drug-Like Properties - RESEARCH TRIANGLE PARK, N.C., July 22, 2008 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing...
